Načítá se...
The Pharmaceutical Industry Tussles Over Biosimilars: Federal and State Decisions Will Have a Big Impact on Pharmacists
Unlike a generic drug, a “generic” biologic won’t be identical to the branded product. Manufacturers are divided over whether pharmacists should have to tell doctors when they prescribe one of the “biosimilars” that will soon appear on the market.
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MediMedia USA, Inc.
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3989078/ https://ncbi.nlm.nih.gov/pubmed/24757365 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|